# Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

> **NCT02484638** · PHASE2,PHASE3 · TERMINATED · sponsor: **CSL Behring** · enrollment: 25 (actual)

## Conditions studied

- Hemophilia A With Inhibitors
- Hemophilia B With Inhibitors

## Interventions

- **DRUG:** CSL689
- **DRUG:** Eptacog alfa (activated)

## Key facts

- **NCT ID:** NCT02484638
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-23
- **Primary completion:** 2018-03-28
- **Final completion:** 2018-03-28
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Business decision non-safety related.
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02484638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02484638, "Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02484638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*